Shareholders' Meeting 2025Assemblée Générale 2025Algemene Vergadering 202524 April 2025 Annual general shareholders’ meeting ENGFRNLSpeech Jean-Christophe Tellier, CEOPDFPDFPDFMinutes AGMPDFPDFPDFConvening Notice(including agenda & attendance formalities)PDFPDFPDFProxyPDFPDFPDFUCB SA/NV - Management Report Statutory accountsPDFPDFPDFUCB SA/NV -Report of the Statutory AuditorPDFPDFPDFUCB Group - 2024 Integrated Annual ReportPDFPDFPDFUCB SA/NVStatutory Annual Accounts 2024PDFPDFPDFUCB Group -2024 Remuneration ReportSee section 3.8 of theCorporate Governance Statementin the Integrated Annual ReportUCB Group -2025 Remuneration PolicyPDFPDFPDFExplanatory note on the 2025 Remuneration PolicyPDFPDFPDFOn the day of publication of the convening notice, UCB SA/NV has a total,of 194 505 658 shares outstanding, of which 189 952 928 are entitled to voteLumi Connect Online Platform - User GuidePDFPDFPDF Proposed dividendThe Board of Directors proposes to pay a gross dividend of € 1.39 per share (gross), to be approved by the annual general meeting of the shareholders.Coupon # 28Ex-dividend: 25 April 2025Record date: 28 April 2025Payment: 29 April 2025Coupon # 28 of UCB shares is payable at € 0.973 net per share after deduction of Belgian withholding tax of 30%*, via our paying agent, KBC Bank NV.* Lower withholding tax rates may be applicable depending on the specific situation of each shareholder. Integrated Annual Report 2024 2024 ONLINE REPORT Shareholders' meeting archives shareholder meeting 2025 shareholder meeting 2024 Shareholders meeting - 2023 Shareholders meeting - 2022 Shareholders meeting - 2021 Shareholders meeting - 2020 Shareholders meeting - 2019 Shareholders meeting - 2018 Shareholders meeting - 2017 Shareholders meeting - 2016 Questions?Please send your questions to shareholders.meeting@ucb.com Re-elected Jonathan PeacockIndependent DirectorChair of the BoardRe-elected in 2025End of term in 2029 BIO - J. Peacock Elected Fiona PowrieIndependent Director Elected in 2025End of term in 2029 BIO - F. Powrie Elected Stef Heylen, MDDirector Elected in 2025End of term in 2029 BIO - S. Heylen